COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
25/03/2026
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
Cellbricks Therapeutics Raises €10 Million New Capital to Move Living Tissue Implants Toward the Clinic
25/03/2026
Funding will accelerate preclinical validation of biofabricated tissue implants for soft tissue repair, wound healing and trauma care - while building the biological and manufacturing foundations for 3D-bioprinted [...]
Verano to Report First Quarter 2026 Financial Results on April 30, 2026
25/03/2026
CHICAGO, March 25, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
25/03/2026
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious [...]
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
25/03/2026
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of [...]
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
25/03/2026
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8: [...]
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue
25/03/2026
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One [...]
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
25/03/2026
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
ADMA Biologics Addresses Misleading Short-Seller Report
25/03/2026
RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to [...]
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
25/03/2026
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
25/03/2026
– TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis – TEV ‘325 was computationally designed using Biolojic’s Multibody [...]
Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026
25/03/2026
NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
25/03/2026
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval
25/03/2026
Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes MINNEAPOLIS, March 25, 2026 (GLOBE [...]
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
25/03/2026
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today [...]
Picard Medical Reports Full Year 2025 Financial Results
25/03/2026
Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems [...]
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
25/03/2026
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. (“Inscobee”) and Apimeds, Inc., (“Apimeds Korea”) today announced that on March 20, 2026, Inscobee [...]
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
25/03/2026
The collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trial TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark [...]
Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers
25/03/2026
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging Clinics TM as [...]

Pages